Siren, L.L.C.
GREENWICH, CT · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 12, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$4.22B2026 Q3+ $12.3M options (notional, not included)
Positions111
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.47.2%
What Changed This Quarter?
Top Holdings
SRRK
Scholar Rock
10.7%
KYMR
Kymera Therapeutics
7.4%
ERAS
Erasca
4.6%
RVMD
Revolution Medicines
4.1%
ONC
BeOne Medicines
4.0%
TNGX
Tango Therapeutics
4.0%
MANE
Veradermics
3.8%
ARWR
Arrowhead Pharmaceuticals
3.5%
New / Increased
18 new · 17 increased
ADRXNEW
ADARx Pharmaceuticals
0.9%
ASNDNEW
Ascendis Pharma A/S
0.7%
DMRANEW
Damora Therapeutics
0.5%
YARWNEW
Yarrow Bioscience
0.4%
SKHYNEW
SK hynix
0.3%
TYRA
Tyra Biosciences
1.8%
+368.4%
ARWR
Arrowhead Pharmaceuticals
3.5%
+33.5%
AMLX
Amylyx Pharmaceuticals
1.7%
+67.5%
Reduced / Exited
37 reduced · 24 sold out
MANE
Veradermics
3.8%
-20.0%
ABVX
Abivax
0.4%
-67.4%
XENE
Xenon Pharmaceuticals
0.6%
-45.5%
KYMR
Kymera Therapeutics
7.4%
-5.1%
EWTX
Edgewise Therapeutics
2.7%
-11.9%
DFTXEXIT
Definium Therapeutics
1.4%
CRNXGBPEXIT
Crinetics Pharmaceuticals
1.1%
COFEXIT
Capital One Finl
0.7%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.